Rivaroxaban and early periprostethic joint infection: our experience.

Acta Biomed · 2017 · PMC6357653 · PMID 29083351

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Chahal et al ( 25 ) noted an increase from 0.9% to 1.9% in infection rate for 160 patients treated with Rivaroxaban after primary THA and TKA (compared with 227 treated with Enoxaparin), even if this difference did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.